恒瑞医药：9款药物获批开展临床试验

Core Viewpoint - 恒瑞医药 has received approval from the National Medical Products Administration for multiple clinical trials of new drug candidates, indicating a significant advancement in its oncology pipeline [1][2][3][4][5] Group 1: Drug Candidates and Their Development - SHR-9839 is a humanized antibody drug targeting advanced solid tumors, with a cumulative R&D investment of approximately 72.31 million yuan [1] - SHR-A2009 is an antibody-drug conjugate targeting HER3, with a cumulative R&D investment of about 227 million yuan; no similar drugs have been approved globally [2] - SHR-1826 is an antibody-drug conjugate targeting c-MET, with a cumulative R&D investment of around 101 million yuan; a similar product has been approved in the U.S. [2] - HRS-4642 is a KRAS G12D inhibitor with a cumulative R&D investment of approximately 191 million yuan; no similar drugs have been approved [2] - 阿得贝利单抗 is a humanized anti-PD-L1 monoclonal antibody that has been approved for use in extensive-stage small cell lung cancer, with a cumulative R&D investment of about 969 million yuan [3] - 注射用瑞康曲妥珠单抗 targets HER2 and has been approved for use in non-small cell lung cancer, with a cumulative R&D investment of around 1.415 billion yuan [4] - SHR-A2102 is an ADC targeting Nectin-4, with a cumulative R&D investment of approximately 248 million yuan; one similar product has been approved [5] - HRS-7058 is a selective small molecule inhibitor for KRAS G12C mutations, with a cumulative R&D investment of about 69.57 million yuan; similar products have been approved [5]